SEC probes four Pharmas for insider trading

The SEC is investigating four pharma deals as part of a larger probe into potential insider trading violations. The deals in question include Pfizer's Wyeth buyout, Merck's purchase of

Drug costs doubled in one decade

Adult prescription drug expenditure doubled from 1996 to 2006, according to a report released by the Agency for Healthcare Research and Quality (AHRQ). "The average expense for a prescription

GSK stakes its emerging markets claim

GlaxoSmithKline has placed many of its eggs in the emerging market basket, and today Abbas Hussain, the company's head of emerging markets, outlined exactly what the company hopes to get out of that

Viehbacher's $9 billion shopping spree

In an article full of juicy tidbits, Bloomberg profiles Chris Viehbacher (photo), the former GlaxoSmithKline CEO-runner up who defected to Sanofi-Aventis. Since joining the company last December,

Pfizer hunting for partners in biosimilar quest

Faced with the prospect of losing billions of dollars to generic competitors, Pfizer is laying the foundation for an ambitious leap into the biosimilar business. David Simmons, who runs Pfizer's

Hamburg has doubts about reimportation

In a letter to Sen. Sam Brownback (R-KA), FDA Commissioner Margaret Hamburg expresses doubts that her agency could properly regulate or guarantee the safety of drugs imported from other countries.

GAO: Post-Vioxx, still no safety changes at FDA

Three years after the Vioxx safety debacle, the FDA has yet to improve its drug safety oversight, according to Government Accountability Office findings. Vioxx was pulled from the market in 2004

More pharma companies raided in EU

European Union antitrust regulators said they made surprise raids on the offices of drugmakers in several European nations Wednesday to seek evidence that they struck anticompetitive business deals

How effective is Roche's Tamiflu, really?

Tamiflu provides only mild protection against complications resulting from influenza. That's according to the Cochrane Collaboration, an independent group that analyzed 20 studies of the drug. The

AZ, Lilly, BMS face steepest patent cliff

AstraZeneca, Eli Lilly and Bristol-Myers Squibb will be facing the biggest patent losses over the next few years, according to a report by Bernstein Research analyst Dr. Tim Anderson. He predicts the

The Top 10 Layoffs of 2009

Welcome to our third annual list of the pharmaceutical industry's top layoffs. With three mega-mergers in 2009, this was a particularly brutal year for job cuts. Not surprisingly, Pfizer (which

Mylan, Wyeth ink Effexor agreements

Mylan Pharmaceuticals has entered into settlement and license agreements with Wyeth, now part of Pfizer, relating to venlafaxine HCl ER capsules in 37.5-, 75- and 150-mg strengths. The product is the

Pharma faces more scrutiny on drug prices

Reports that drug prices have risen nearly 10 percent this year put the pharmaceutical industry under the microscope this morning. Last month the AARP released a report on the rapidly-rising cost of

DTC spending up in Q3

Following several quarters of sliding DTC ad spending, TNS Media Intelligence data shows that pharma DTC advertising rose to $1.16 billion, up 15 percent from the same period last year. That's a big

Novartis' Tasigna beats Glivec in leukemia study

More news from the American Society of Hematology meeting: In the first head-to-head comparison of Novartis' Tasigna and its older medicine Glivec (also known as Gleevec), Tasigna results showed

Grassley asks AMA, others for payment data

Sen. Charles Grassley has sent letters to 33 industry groups--including the American Medical Association and American Cancer Society--requesting that the organizations reveal industry funding. The

Celgene touts Revlimid as first-line treatment

Celegene's Revlimid is effective as a first-line therapy for multiple myeloma, according to data from a new study. The drug is already approved as a second-line treatment for patients who haven't

Ruling could prevent whistleblower suits

Things may have just gotten tougher for potential pharma whistleblowers. Last Friday, the U.S. Court of Appeals for the Eleventh Circuit in Atlanta upheld a lower court's dismissal of a whistleblower

Zyprexa, Seroquel expanded to teenagers

The FDA has approved the use of Eli Lilly's Zyprexa and AstraZeneca's Seroquel in teenagers with schizophrenia and bipolar disorder. But the agency will be looking for more data on the side effects

$30K per month: Too much for a cancer drug?

How much is too much to pay for a cancer drug? New York Times healthcare writer Andrew Pollack examines the case of Folotyn, Allos Therapeutics' recently-approved cancer drug. Folotyn is indicated